ArticleJBRA assisted reproduction2026
Effectiveness of BMMSC and Dienogest on IL-1β, IL-8 Expression and Lesion Area in Endometriosis Mice.
Article in JBRA assisted reproduction, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveEndometriosis is a chronic estrogen-dependent inflammatory disease that impairs fertility and quality of life. Dienogest, the current standard therapy, provides symptom relief but does not correct immune imbalance or prevent recurrence. Bone marrow-derived mesenchymal stem cells (BMMSCs), with strong immunomodulatory potential, may represent a disease-modifying alternative. This study evaluated the effects of BMMSCs, Dienogest, and their combination on IL-1β and IL-8 expression and lesion size in a murine endometriosis model.
methodsThe experiment was conducted between August and December 2024 using 32 female mice, randomly assigned into four groups: untreated endometriosis controls (K+), BMMSC monotherapy (P1), BMMSC combined with Dienogest (P2), and Dienogest monotherapy (P3). Mice were injected intraperitoneally with endometrial fragments (200 μL) to become endometriosis models. On day 15, the models received mesenchymal stem cells. Sample collection was on day 29. Cytokine expression (IL-1β and IL-8) was assessed immunohistochemically, while lesion dimensions were analyzed using ImageJ v1.54 (NIH, USA) software. Immunofluorescence confirmed the BMMSC phenotype (CD73+, CD90+, CD105+, CD45-). Statistical analysis used one-way ANOVA and Kruskal-Wallis with Bonferroni correction.
resultsBMMSC monotherapy resulted in the most pronounced suppression of IL-1β and IL-8 expression, alongside a significant reduction in lesion size (p<0.001). All treatment groups differed significantly from the control group.
conclusionsBMMSC monotherapy in endometriosis mice models markedly reduced IL-1β and IL-8 expression, decreased lesion size, and demonstrated more robust disease-modifying activity compared to Dienogest or combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.